References

  1. Kutikov A, Crispen PL, Uzzo RG. Pathophysiology, Evaluation, and Medical Management of Adrenal Disorders. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA, eds. Campbell-Walsh Urology. 10th ed. Philadelphia: Elsevier; 2011:1685-1736.

  2. Song JH, Chaudhry FS, Mayo-Smith WW. The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR Am J 
Roentgenol 2008;190:1163-1168.

  3. Russell RP, Masi AT, Richter ED. Adrenal cortical adenomas and hypertension. A clinical pathologic analysis of 690 cases with matched controls and a review of the literature. Medicine (Baltimore)
1972;51:211-225.

  4. Young W. Management approaches to adrenal incidentalomas: A view from Rochester, Minnesota. Endocrinol Metab Clin North Am 2000;29:159-185.

  5. Kutikov A, Mallin K, Canter D, et al. Effects of increased cross-sectional imaging on the diagnosis and prognosis of adrenocortical carcinoma: analysis of the National Cancer Database. J Urol 2011;186:805-810.

  6. Young WF, Jr. The Incidentally Discovered Adrenal Mass. N Engl J Med. 2007;356:601-610.

  7. Barzon L, Sonino N, Fallo F, et al. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003;149:273-285.

  8. Boland GW. Adrenal imaging: why, when, what, and how? Part 3. The algorithmic approach to definitive characterization of the adrenal incidentaloma? AJR Am J Roentgenol 2011;196:W109-111.

  9. Lee MJ, Hahn PF, Papanicolaou N, et al. Benign and malignant adrenal masses: CT distinction with attenuation coefficients, size, and observer analysis. Radiology 1991;179:415-418.

  10. Korobkin M, Brodeur F, Yutzy G, et al. Differentiation of adrenal adenomas from nonadenomas using CT attenuation values. Am. J. Roentgenol 1996;166:531-536.

  11. Boland GW, Blake MA, Hahn PF, Mayo-Smith WW. Incidental adrenal lesions: principles, techniques, and algorithms for imaging characterization. Radiology 2008;249:756-775.

  12. Boland G, Lee M, Gazelle G, et al. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. Am. J. Roentgenol 1998;171:201-204.

  13. Pena CS, Boland GWL, Hahn PF, et al. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology 2000;217:798-802.

  14. Bhargav P, Mishra A, Agarwal G, et al. Adrenal incidentalomas: experience in a developing country. World J Surg 2008;32:1802-1808.

  15. Simhan J, Canter D, Teper E, et al. Adrenocortical carcinoma masquerading as a benign adenoma on computed tomography washout study. Urology 2012;79:e19-20.

  16. Blake MA, Kalra MK, Sweeney AT, et al. Distinguishing benign from malignant adrenal masses: multi-detector row CT protocol with 10-minute delay. Radiology. 2006;238:578-585.

  17. Szolar DH, Kammerhuber FH. Adrenal adenomas and nonadenomas: assessment of washout at delayed contrast-enhanced CT. Radiology 1998;207:369-375.

  18. Hussain HK, Korobkin M. MR imaging of the adrenal glands. Magn Reson Imaging Clin N Am 2004;12:515-544.

  19. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. J Clin Endocrinol Metab 2000;85:637-644.

  20. Angeli A, Osella G, Ali A, Terzolo M. Adrenal incidentaloma: An overview of clinical and epidemiological data from the National Italian Study Group. Horm Res 1997;47:279-283.

  21. Caoili EM, Korobkin M, Francis IR, et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 2002;222:629-633.

  22. Barry MK, van Heerden JA, Farley DR, Grant CS, Thompson GB, Ilstrup M.S DM. Can adrenal incidentalomas be safely observed? World J Surg 1998;22:599-603.

  23. Thompson GB, Young WF Jr. Adrenal incidentaloma. Curr Opin Oncol 2003;15:84-90.

  24. Grumbach MM, Biller BMK, Braunstein GD, et al. Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann Intern Med 2003;138:424-429.

  25. Libe R, Dall’Asta C, Barbetta L, et al. Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol 2002;147:489-494.

  26. Welch TJ, Sheedy PF, 2nd, Stephens DH, Johnson CM, Swensen SJ. Percutaneous adrenal biopsy: review of a 10-year experience. Radiology 1994;193:341-344.

  27. Quayle FJ, Spitler JA, Pierce RA, et al. Needle biopsy of incidentally discovered adrenal masses is rarely informative and potentially hazardous. Surgery 2007;142:497-504.

  28. Silverman SG, Mueller PR, Pinkney LP, et al. Predictive 
value of image-guided adrenal biopsy: analysis of results of 101 biopsies. Radiology 1993;187:715-718.

  29. Young WF, Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 2007;356:601-610.

  30. Blake MA, Krishnamoorthy SK, Boland GW, et al. Low-density pheochromocytoma on CT: a mimicker of adrenal adenoma. Am J Roentgenol 2003;181:1663-1668.

  31. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008;93:1526-1540.

  32. Findling JW, Raff H. Cushing’s Syndrome: important issues in diagnosis and management. J Clin 
Endocrinol Metab 2006;91:3746-3753.

  33. Grossman A, Pacak K, Sawka A, et al. Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus? Ann N Y Acad Sci 2006;1073:332-347.

  34. Eisenhofer G, Siegert G, Kotzerke J, et al. Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas 
and paragangliomas. Horm Metab Res 2008;
40:329-337.

  35. Montori VM, Young WF, Jr. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am 2002;31:619-632.

  36. Mulatero P, Morello F, Veglio F. Genetics of primary aldosteronism. J Hypertens 2004;22:663-670.

  37. Vierhapper H. Determination of the aldosterone/renin ratio in 269 patients with adrenal incidentaloma. 
Exp Clin Endocrinol Diabetes 2007;115:518-521.

  38. Cordera F, Grant C, van Heerden J, et al. 
Androgen-secreting adrenal tumors. Surgery 2003;134:874-880.

  39. Moreno S, Montoya G, Armstrong J, et al. Profile and outcome of pure androgen-secreting adrenal tumors in women: experience of 21 cases. Surgery 2004;136:1192-1198.

  40. Nickelsen T, Lissner W, Schoffling K. The dexamethasone suppression test and long-term contraceptive treatment: measurement of ACTH or salivary cortisol does not improve the reliability of the test. Exp Clin Endocrinol 1989;94:275-280.

  41. Eisenhofer G. Editorial: biochemical diagnosis of pheochromocytoma-is it time to switch to plasma-free metanephrines? J Clin Endocrinol Metab 2003;88:550-552.

  42. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol 2007;66:607-618.

  43. Simhan J, Smaldone MC, Canter DJ, et al. Trends in regionalization of adrenalectomy to higher volume surgical centers. J Urol 2012;188:377-382.